Cellis Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series A
  • (Bidding)

  • Latest Deal Amount
  • $29.6M

  • Investors
  • 2

Cellis General Information

Description

Developer of macrophage-based cancer immunotherapies designed to target hypoxic tumor regions and activate the immune system. The company utilizes a proprietary biological mechanism to deliver drug conjugates to cold and heterogeneous tumors, enabling healthcare providers to overcome antigen escape and improve treatment outcomes for complex cancers.

Contact Information

Website
cellis.eu
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Gubelstrasse 15
  • 6300 Zug
  • Switzerland
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • Gubelstrasse 15
  • 6300 Zug
  • Switzerland

Cellis Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cellis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series A) 24-Feb-2026 $29.6M Bidding Clinical Trials - Phase 1
10. Later Stage VC 28-Nov-2025 Completed Clinical Trials - Phase 1
9. Grant 01-Sep-2024 Completed Pre-Clinical Trials
8. Grant 01-Aug-2024 Completed Pre-Clinical Trials
7. Grant 01-Jan-2023 Completed Pre-Clinical Trials
6. Grant 01-Sep-2022 Completed Pre-Clinical Trials
5. Grant 01-Jun-2022 Completed Pre-Clinical Trials
4. Dividend Recapitalization 01-Apr-2022 Completed Pre-Clinical Trials
3. Grant 15-Jul-2020 $113K $1.71M Completed Startup
2. Early Stage VC (Series 1) 12-Jan-2019 $1.71M $1.71M Completed Startup
To view Cellis’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Cellis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of macrophage-based cancer immunotherapies designed to target hypoxic tumor regions and activate the immune sy
Biotechnology
Zug, Switzerland
10 As of 2026

Bothell, WA
 

Epalinges, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cellis Competitors (3)

One of Cellis’s 3 competitors is Seagen, a Formerly VC-backed company based in Bothell, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seagen Formerly VC-backed Bothell, WA
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland
Summit Therapeutics Formerly VC-backed Miami, FL
You’re viewing 3 of 3 competitors. Get the full list »

Cellis Patents

Cellis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026132100-A1 Isolated targeted delivery system for the treatment of bladder cancer Pending 20-Dec-2024
WO-2026132420-A1 Isolated targeted delivery system for the treatment of head and neck cancer Pending 20-Dec-2024
WO-2026120029-A1 Improved isolated targeted delivery system Pending 03-Dec-2024
WO-2025083276-A1 Improved isolated targeted delivery system Inactive 19-Oct-2023
EP-4637829-A1 Isolated targeted delivery system for the treatment of ovarian cancer Pending 20-Dec-2022 A61K47/64
To view Cellis’s complete patent history, request access »

Cellis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cellis Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Horizon 2020 Government
Twiti Investments Venture Capital Minority
To view Cellis’s complete investors history, request access »

Cellis FAQs

  • When was Cellis founded?

    Cellis was founded in 2015.

  • Where is Cellis headquartered?

    Cellis is headquartered in Zug, Switzerland.

  • What is the size of Cellis?

    Cellis has 10 total employees.

  • What industry is Cellis in?

    Cellis’s primary industry is Biotechnology.

  • Is Cellis a private or public company?

    Cellis is a Private company.

  • What is Cellis’s current revenue?

    The current revenue for Cellis is .

  • How much funding has Cellis raised over time?

    Cellis has raised $13.3M.

  • Who are Cellis’s investors?

    Horizon 2020 and Twiti Investments have invested in Cellis.

  • Who are Cellis’s competitors?

    Seagen, ADC Therapeutics, and Summit Therapeutics are competitors of Cellis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process